Recruiting PHASE4 INTERVENTIONAL 1-arm
NCT07268222
Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS) (MOMACS)
Sponsor: Laikο General Hospital, Athens
Conditions
Mild Autonomous Cortisol Secretion (MACS)
Updated 1 time since 2026 Last updated: Dec 3, 2025 Started: Dec 1, 2025 Primary completion: Nov 1, 2026 Completion: Nov 25, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07268222, this PHASE4 trial focuses on Mild Autonomous Cortisol Secretion (MACS) and remains actively recruiting participants. Sponsored by Laikο General Hospital, Athens, it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Recruiting — PHASE4
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Laikο General Hospital, Athens
Data source: Laikο General Hospital, Athens
For direct contact, visit the study record on ClinicalTrials.gov .